
-
Corvus NASDAQ:CRVS Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells in preclinical studies. CPI-006 is being evaluated in a Phase 3 clinical trial for the treatment of hospitalized patients with COVID-19 and in a multicenter Phase 1/1b oncology clinical trial as a single agent, in combination with ciforadenant and pembrolizumab. The Company's second clinical program, CPI-818, is an investigational, oral, small molecule drug that selectively inhibited ITK in preclinical studies, and is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. Its third clinical program, ciforadenant (CPI-444), is an oral, small molecule inhibitor of the A2A receptor.
Location: 863 Mitten Rd Ste 102, California, 94010-1311, US | Website: www.corvuspharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
143.3M
Cash
51.96M
Avg Qtr Burn
-6.356M
Short % of Float
10.31%
Insider Ownership
3.25%
Institutional Own.
55.43%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Soquelitinib (CPI-818) Details Cancer, Blood cancer, Peripheral T-cell Lymphomas | Phase 3 Data readout | |
Soquelitinib Details Autoimmune Lymphoproliferative Syndrome | Phase 2 Data readout | |
Mupadolimab (CPI-006) Details Cancer, Lung cancer, Renal cell carcinoma, Non-small cell lung carcinoma | Phase 2 Update | |
Soquelitinib (CPI-818) Details Cancer, Renal cell carcinoma (renal cell cancer) | Phase 2 Initiation | |
Ciforadenant +/- ipilimumab and nivolumab Details Cancer, 1L metastatic renal cell carcinoma (renal cell cancer) | Phase 1/2 Data readout | |
Mupadolimab + pembrolizumab Details Cancer, Head and neck cancer, Non-small cell lung carcinoma | Phase 1 Data readout | |
Soquelitinib (CPI-818) Details Skin disease/disorder, Atopic dermatitis | Phase 1 Data readout | |
Mupadolimab (CPI-0060) Details COVID-19 | Failed Discontinued |